EMA's CHMP Recommends Not Granting Marketing Authorisation For Eli Lilly's Kisunla
Reuters
28 Mar
March 28 (Reuters) - EMA's CHMP: : *EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR KISUNLA (DONANEMAB) *EMA'S CHMP: RECOMMENDED TO REFUSE EXTENDING MARKETING AUTHORISATION FOR PEMAZYRE (PEMIGATINIB) *EMA'S CHMP:APPLICATION TO EXTEND USE OF AMYVID IN ADULTS TO MONITOR RESPONSE TO TREATMENTS THAT REDUCE BETA AMYLOID PLAQUES WAS WITHDRAWN *EMA'S CHMP: FOR OPDIVO, RECOMMENDED A NEW PHARMACEUTICAL FORM AND NEW STRENGTH FOR SUBCUTANEOUS ADMINISTRATION *EMA'S CHMP: CONCLUDED BENEFITS OF MYSIMBA CONTINUE TO OUTWEIGH ITS RISKS
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.